This trial compares cabozantinib to placebo in treating neuroendocrine or carcinoid tumors. Cabozantinib is a chemotherapy drug that targets specific tyrosine kinase receptors, which when blocked, may slow tumor growth.
1 Primary · 3 Secondary · Reporting Duration: Up to 8 years
Experimental Treatment
Non-Treatment Group
395 Total Participants · 2 Treatment Groups
Primary Treatment: Cabozantinib S-malate · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
18 - 65 | 100.0% |
Epic Care-Dublin | 100.0% |
Met criteria | 100.0% |